These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 9419821)

  • 21. Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: long-term clinical and functional prognosis.
    Fragasso G; Chierchia SL; Arioli F; Carandente O; Gerosa S; Carlino M; Palloshi A; Gianolli L; Calori G; Fazio F; Margonato A
    Int J Cardiol; 2009 Oct; 137(2):137-44. PubMed ID: 18762343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of atenolol on QT interval and dispersion in patients with syndrome X.
    Leonardo F; Fragasso G; Rosano GM; Pagnotta P; Chierchia SL
    Am J Cardiol; 1997 Sep; 80(6):789-90. PubMed ID: 9315593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Assessing myocardial viability in chronic myocardial infarct with 18F-fluoro-D-glucose positron emission tomography and 99mTc-MIBI SPECT].
    Schneider CA; Voth E; Theissen P; Wienhard K; Wagner R; Baer FM; Sechtem U; Schicha H
    Z Kardiol; 1994 Feb; 83(2):124-31. PubMed ID: 8165842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent twenty-four hour SPECT thallium-201 defects, plasma thallium-201 concentrations and PET metabolic viability.
    Brunken RC; Mody FV; Hawkins RA; Nienaber CA; Phelps ME; Schelbert HR
    Herz; 1994 Feb; 19(1):28-41. PubMed ID: 8150412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET.
    Knuuti MJ; Nuutila P; Ruotsalainen U; Teräs M; Saraste M; Härkönen R; Ahonen A; Wegelius U; Haapanen A; Bergman J
    J Nucl Med; 1993 Dec; 34(12):2068-75. PubMed ID: 8254389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of myocardial viability and coronary revascularization on clinical outcome and prognosis: a follow-up study of 161 patients with coronary heart disease].
    vom Dahl J; Altehoefer C; Büchin P; Sheehan FH; Schwarz ER; Koch KC; Schulz G; Uebis R; Schöndube F; Messmer BJ; Büll U; Hanrath P
    Z Kardiol; 1996 Nov; 85(11):868-81. PubMed ID: 9064949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relation between myocardial perfusion, myocardial necrosis and residual glucose metabolism as a vitality parameter in the post-ischemic myocardium following coronary reperfusion].
    Sochor H
    Acta Med Austriaca Suppl; 1989; 39():1-36. PubMed ID: 2787948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation between the kinetics of thallium-201 in myocardial scintigraphy and myocardial metabolism in patients with acute myocardial infarction.
    Yamagishi H; Akioka K; Takagi M; Tanaka A; Takeuchi K; Yoshikawa J; Ochi H
    Heart; 1998 Jul; 80(1):28-34. PubMed ID: 9764055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac syndrome X, intraventricular gradients and, beta-blockers.
    Cotrim C; Almeida AG; Carrageta M
    Rev Port Cardiol; 2010 Feb; 29(2):193-203. PubMed ID: 20545247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Changes in myocardial Tc-99m-sestamibi uptake in asynergic territories during low-dose echo-dobutamine test].
    Leoncini M; Marcucci G; Magni M; Silvestri M; Traini AM; Arena A; Mondanelli D; Giovannini T; Paoletti M; Bardazzi L; Mennuti A; Petrella A
    G Ital Cardiol; 1996 Nov; 26(11):1243-55. PubMed ID: 9036021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial beta-adrenoceptor density and plasma catecholamines in syndrome X.
    Rosen SD; Boyd H; Rhodes CG; Kaski JC; Camici PG
    Am J Cardiol; 1996 Jul; 78(1):37-42. PubMed ID: 8712115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability.
    Meeder JG; Blanksma PK; Crijns HJ; Anthonio RL; Pruim J; Brouwer J; de Jong RM; van der Wall EE; Vaalburg W; Lie KI
    Eur Heart J; 1995 Nov; 16(11):1571-7. PubMed ID: 8881850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coronary autoregulation is abnormal in syndrome X: insights using myocardial contrast echocardiography.
    Rinkevich D; Belcik T; Gupta NC; Cannard E; Alkayed NJ; Kaul S
    J Am Soc Echocardiogr; 2013 Mar; 26(3):290-6. PubMed ID: 23313388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiographic evaluation of myocardial perfusion in patients with syndrome X.
    Atmaca Y; Ozdemir AO; Ozdol C; Oguz D; Gulec S; Kumbasar D; Erol C
    Am J Cardiol; 2005 Sep; 96(6):803-5. PubMed ID: 16169365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angina with normal coronary arteries: diagnosis, pathophysiology and treatment.
    Chierchia SL; Fragasso G
    Eur Heart J; 1996 Dec; 17 Suppl G():14-9. PubMed ID: 8960450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perfusion abnormality, normal coronaries, and chest pain.
    Pennell DJ
    J Am Coll Cardiol; 2008 Jan; 51(4):473-5. PubMed ID: 18222359
    [No Abstract]   [Full Text] [Related]  

  • 37. Perfusion heterogeneity in syndrome X.
    Boudík F; Anger Z
    Eur Heart J; 1996 Nov; 17(11):1759-60. PubMed ID: 8922931
    [No Abstract]   [Full Text] [Related]  

  • 38. Syndrome X.
    Sylvén C
    J Intern Med; 1993 Oct; 234(4):431-3. PubMed ID: 8409842
    [No Abstract]   [Full Text] [Related]  

  • 39. Ionophoric action on the cellular membrane as a pathophysiological mechanism in syndrome X: myth or reality?
    Waldenström A; Ronquist G
    J Intern Med; 1995 Sep; 238(3):187-9. PubMed ID: 7673847
    [No Abstract]   [Full Text] [Related]  

  • 40. Abnormal myocardial glucose handling in patients with syndrome X: effect of beta-adrenergic blockade.
    Fragasso G; Chierchia SL; Rossetti E; Landoni C; Lucignani G; Fazio F
    G Ital Cardiol; 1997 Nov; 27(11):1113-20. PubMed ID: 9419821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.